Project Grant R00HL177831
Award Date
4/1/25
Completion Date
5/31/28
Dollars Obligated
$465K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Bloodworks (ZN56PFWUDQK7)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $827,753.90 to Bloodworks (doing business as Puget Sound Blood Center and Program) to investigate the role of thiol isomerases, particularly protein disulfide isomerase (PDI), in promoting redox-sensitive vaso-occlusion in sickle cell disease. The research aims to mechanistically examine how oxidative stress and cysteine...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Duke University a $637,526 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to study the effects of sickle red blood cells (RBCs) on neutrophil activation and phenotypes in sickle cell disease. The research aims to systematically define the characteristics of sickle RBCs that cause neutrophil activation and the resulting functional, phenotypic, and transcriptional changes in neutrophils. The findings...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will provide $1,276,908 in funding to Bloodworks, doing business as Puget Sound Blood Center and Program, from March 1, 2025 to February 28, 2032.
The award will support molecular and translational research studies on the mechanisms of disease in von Willebrand disease (VWD) and sickle cell disease (SCD), both of which involve the protein von...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $128,100.00 to the New York Blood Center, Inc. to evaluate methods for improving the homing and engraftment efficiency of CD34+ cells from sickle cell disease (SCD) patients. The goal is to address barriers to equitable access to SCD gene therapy, which often requires extensive leukapheresis and myeloablative conditioning. The...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Emory University a $101,183 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program. The grant, titled "Investigating the Role of Heme-Induced Complement Activation in SCD Pregnancy", aims to characterize the effects of sickle cell disease (SCD) and heme-induced complement activation on pregnancy outcomes, and determine if heme and/or complement modulation can improve pregnancy outcomes in a mouse...
The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research grant program (CFDA 93.837), awarded a $265,347 Project Grant to Functional Fluidics Inc. to develop and validate a point-of-care (POC) device for assessing red blood cell sickling in sickle cell disease (SCD) patients. The goal is to create a simple, standalone, and potentially CLIA-waived POC system that can measure oxygen-induced sickling to assist in monitoring SCD patient condition and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $607,535 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to the University of Illinois to study the effects of hemin on the pulmonary endothelium and its role in the pulmonary complications of sickle cell disease. The research aims to evaluate the specific effects of chronic, low concentration hemin on the development of pulmonary vascular remodeling and pulmonary hypertension, as well as the acute effects of high...
The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $608,126 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to the Regents of the University of Minnesota to develop and validate single-cell biomarkers for predicting clinical outcomes in sickle cell disease. The project aims to: (1) define the relationship between sickle cell disease adverse outcomes and single-cell biochemical/mechanical properties, (2) identify biomarkers for favorable/unfavorable response to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) totals $445,000 and will fund research to characterize the role of neutrophil extracellular traps (NETs) in immune homeostasis and investigate the potential of NET-directed therapeutics in sepsis and sickle cell disease.
The research aims to fill knowledge gaps in understanding the protective and detrimental effects of NETs, and to define the...
This federal Project Grant award of $169,156 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research conducted by The Washington University to optimize hematopoietic stem cell transplantation (HSCT) for treating non-malignant diseases, with a focus on sickle cell disease (SCD).
The key objectives of this 5-year award are to: 1) Evaluate novel stem cell mobilization regimens to generate a sufficient...